Novartis Says Phase III Data In Lancet Show Significant Benefit Of Afinitor RTT News Swiss drug maker Novartis AG (NVS: Quote) said Thursday that Phase III data published in the Lancet showed significant benefit of cancer drug Afinitor or everolimus in patients with non-cancerous tumors associated with tuberous sclerosis complex or TSC ... Phase III Data in The Lancet Show Significant Benefit of Novartis Drug ... Novartis says Afinitor reduces tumors in rare genetic disease |
